John B. McIntyre
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
John B. McIntyre has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Bachisio Ziccheddu
Sheila and David Fuente Cancer Biology Graduate Program, University of Miami Miller School of Medicine, Miami, Florida
4 shared publications - Benjamin Diamond
Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, USA
4 shared publications - Francesco Maura
Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
4 shared publications - Holly Lee
Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada
4 shared publications - Katalin Osz
Cancer Translational Research Core, Arthur Child Cancer Centre, Calgary, Canada
4 shared publications - Leo Rasche
Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany
4 shared publications
Latest Publications
- Open Access
- 13 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
Use of circulating microRNAs to identify high-risk adenomas among FIT+ patients undergoing screening colonoscopy
Background: Colonoscopy prevents colorectal cancer (CRC) but is invasive and resource intensive. Circulating microRNAs (miRNAs) may improve risk stratification of fecal immunochemical test (FIT)-positive individuals by identifying high-risk adenomas (HRAs). We evaluated the association of circulating miRNAs with HRAs and their contribution to risk prediction models (RPMs). Methods: We analyzed 398 FIT-positive participants from a Canadian screening cohort (160 HRAs; 238 controls). Plasma miRNAs were quantified using NanoString nCounter. Differential expression was assessed using two-tailed t-tests with Bonferroni correction, and LASSO regression identified predictive miRNAs. Five RPMs were developed (Baseline, Bonferroni, Bonferroni+Baseline, LASSO, LASSO+Baseline) and evaluated using AUCs, DeLong's test, calibration, bootstrap validation, and decision curve analysis. Results: Eleven miRNAs were Bonferroni-significant, and LASSO retained 8 predictors. The Baseline model had an optimism-corrected AUC of 0.61, increasing to 0.80 with these miRNAs and 0.82 with baseline variables added; the LASSO+Baseline model achieved an AUC of 0.82 with good calibration. All miRNA-enhanced models outperformed Baseline (P<0.001) and showed greater net benefit on decision curve analysis. At a 20% threshold, the LASSO+Baseline model achieved 95.0% sensitivity and 56.7% PPV. Conclusions Circulating miRNAs substantially improved identification of HRAs among FIT-positive individuals with clinical utility. Impact: These data support further evaluation of miRNA-informed RPMs to refine CRC screening.
- 13 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
Open AccessUse of circulating microRNAs to identify high-risk adenomas among FIT+ patients undergoing screening colonoscopy
Background: Colonoscopy prevents colorectal cancer (CRC) but is invasive and resource intensive. Circulating microRNAs (miRNAs) may improve risk stratification of fecal immunochemical test (FIT)-positive individuals by identifying high-risk adenomas (HRAs). We evaluated the association of circulating miRNAs with HRAs and their contribution to risk prediction models (RPMs). Methods: We analyzed 398 FIT-positive participants from a Canadian screening cohort (160 HRAs; 238 controls). Plasma miRNAs were quantified using NanoString nCounter. Differential expression was assessed using two-tailed t-tests with Bonferroni correction, and LASSO regression identified predictive miRNAs. Five RPMs were developed (Baseline, Bonferroni, Bonferroni+Baseline, LASSO, LASSO+Baseline) and evaluated using AUCs, DeLong's test, calibration, bootstrap validation, and decision curve analysis. Results: Eleven miRNAs were Bonferroni-significant, and LASSO retained 8 predictors. The Baseline model had an optimism-corrected AUC of 0.61, increasing to 0.80 with these miRNAs and 0.82 with baseline variables added; the LASSO+Baseline model achieved an AUC of 0.82 with good calibration. All miRNA-enhanced models outperformed Baseline (P<0.001) and showed greater net benefit on decision curve analysis. At a 20% threshold, the LASSO+Baseline model achieved 95.0% sensitivity and 56.7% PPV. Conclusions Circulating miRNAs substantially improved identification of HRAs among FIT-positive individuals with clinical utility. Impact: These data support further evaluation of miRNA-informed RPMs to refine CRC screening.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S2 from Timing Genomic Antigen Loss in Multiple Myeloma Treated with T Cell–Redirecting Immunotherapies
Table S1: Clinical and sample data for patients in the study cohort. Table S2: GPRC5D and TNFRSF17 mutations from baseline samples in the CoMMpass dataset.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S2 from Timing Genomic Antigen Loss in Multiple Myeloma Treated with T Cell–Redirecting Immunotherapies
Table S1: Clinical and sample data for patients in the study cohort. Table S2: GPRC5D and TNFRSF17 mutations from baseline samples in the CoMMpass dataset.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Timing Genomic Antigen Loss in Multiple Myeloma Treated with T Cell–Redirecting Immunotherapies
Genomic antigen loss is a recurring mechanism of resistance to chimeric antigen receptor T-cell (CAR-T) and T-cell engagers (TCE) in relapsed/refractory multiple myeloma (RRMM). Yet, it remains unclear whether these events are acquired under treatment or merely selected from preexisting, undetectable clones. By leveraging chemotherapy mutational signatures as temporal barcodes within whole-genome sequencing data, we could time genomic antigen escape in 4 of 11 patients with RRMM. In all cases, the biallelic loss was driven by genomic events acquired after exposure to BCMA- and GPCR5D-targeted CAR-T/TCE and not present at baseline. Longitudinal digital PCR analysis corroborated that resistance mutations were undetectable at therapy initiation but emerged preceding relapse. Among 752 newly diagnosed patients, only 2.7% and 9% had monoallelic inactivation of TNFRSF17 and GPCR5D, respectively, with no biallelic loss. Our findings suggest limited utility of mutational screening prior to CAR-T/TCE while underscoring the importance of dynamic surveillance during therapy.Significance:Multiple myeloma has been demonstrated to recurrently develop resistance to T-cell redirection via genomic antigen escape. By leveraging chemotherapy mutational signatures, we demonstrate that somatic antigen-escape mechanisms are uniformly acquired following treatment initiation and not selected from among preexisting clones, emphasizing the importance of dynamic longitudinal surveillance for their emergence.See related commentary by Kauer et al., p. 532
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Timing Genomic Antigen Loss in Multiple Myeloma Treated with T Cell–Redirecting Immunotherapies
Genomic antigen loss is a recurring mechanism of resistance to chimeric antigen receptor T-cell (CAR-T) and T-cell engagers (TCE) in relapsed/refractory multiple myeloma (RRMM). Yet, it remains unclear whether these events are acquired under treatment or merely selected from preexisting, undetectable clones. By leveraging chemotherapy mutational signatures as temporal barcodes within whole-genome sequencing data, we could time genomic antigen escape in 4 of 11 patients with RRMM. In all cases, the biallelic loss was driven by genomic events acquired after exposure to BCMA- and GPCR5D-targeted CAR-T/TCE and not present at baseline. Longitudinal digital PCR analysis corroborated that resistance mutations were undetectable at therapy initiation but emerged preceding relapse. Among 752 newly diagnosed patients, only 2.7% and 9% had monoallelic inactivation of TNFRSF17 and GPCR5D, respectively, with no biallelic loss. Our findings suggest limited utility of mutational screening prior to CAR-T/TCE while underscoring the importance of dynamic surveillance during therapy.Significance:Multiple myeloma has been demonstrated to recurrently develop resistance to T-cell redirection via genomic antigen escape. By leveraging chemotherapy mutational signatures, we demonstrate that somatic antigen-escape mechanisms are uniformly acquired following treatment initiation and not selected from among preexisting clones, emphasizing the importance of dynamic longitudinal surveillance for their emergence.See related commentary by Kauer et al., p. 532
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S3 from Timing Genomic Antigen Loss in Multiple Myeloma Treated with T Cell–Redirecting Immunotherapies
Supplemental Figure 1: Swimmer plot of all cases described in the manuscript. Supplemental Figure 2: The 96-mutational profile of the truncal mutations per each of patients that can be timed, revealing a distinct, clonal melphalan signature profile (SBS-MM1/SBS99). Supplemental Figure 3: Additional Cases for which antigen escape timing was not possible.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S3 from Timing Genomic Antigen Loss in Multiple Myeloma Treated with T Cell–Redirecting Immunotherapies
Supplemental Figure 1: Swimmer plot of all cases described in the manuscript. Supplemental Figure 2: The 96-mutational profile of the truncal mutations per each of patients that can be timed, revealing a distinct, clonal melphalan signature profile (SBS-MM1/SBS99). Supplemental Figure 3: Additional Cases for which antigen escape timing was not possible.
- 4 September 2025
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 6 (6) , 572-579
Timing Genomic Antigen Loss in Multiple Myeloma Treated with T Cell–Redirecting Immunotherapies
Genomic antigen loss is a recurring mechanism of resistance to chimeric antigen receptor T-cell (CAR-T) and T-cell engagers (TCE) in relapsed/refractory multiple myeloma (RRMM). Yet, it remains unclear whether these events are acquired under treatment or merely selected from preexisting, undetectable clones. By leveraging chemotherapy mutational signatures as temporal barcodes within whole-genome sequencing data, we could time genomic antigen escape in 4 of 11 patients with RRMM. In all cases, the biallelic loss was driven by genomic events acquired after exposure to BCMA- and GPCR5D-targeted CAR-T/TCE and not present at baseline. Longitudinal digital PCR analysis corroborated that resistance mutations were undetectable at therapy initiation but emerged preceding relapse. Among 752 newly diagnosed patients, only 2.7% and 9% had monoallelic inactivation of TNFRSF17 and GPCR5D, respectively, with no biallelic loss. Our findings suggest limited utility of mutational screening prior to CAR-T/TCE while underscoring the importance of dynamic surveillance during therapy. Significance: Multiple myeloma has been demonstrated to recurrently develop resistance to T-cell redirection via genomic antigen escape. By leveraging chemotherapy mutational signatures, we demonstrate that somatic antigen-escape mechanisms are uniformly acquired following treatment initiation and not selected from among preexisting clones, emphasizing the importance of dynamic longitudinal surveillance for their emergence. See related commentary by Kauer et al., p. 532
- 4 September 2025
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 6 (6) , 572-579
Timing Genomic Antigen Loss in Multiple Myeloma Treated with T Cell–Redirecting Immunotherapies
Genomic antigen loss is a recurring mechanism of resistance to chimeric antigen receptor T-cell (CAR-T) and T-cell engagers (TCE) in relapsed/refractory multiple myeloma (RRMM). Yet, it remains unclear whether these events are acquired under treatment or merely selected from preexisting, undetectable clones. By leveraging chemotherapy mutational signatures as temporal barcodes within whole-genome sequencing data, we could time genomic antigen escape in 4 of 11 patients with RRMM. In all cases, the biallelic loss was driven by genomic events acquired after exposure to BCMA- and GPCR5D-targeted CAR-T/TCE and not present at baseline. Longitudinal digital PCR analysis corroborated that resistance mutations were undetectable at therapy initiation but emerged preceding relapse. Among 752 newly diagnosed patients, only 2.7% and 9% had monoallelic inactivation of TNFRSF17 and GPCR5D, respectively, with no biallelic loss. Our findings suggest limited utility of mutational screening prior to CAR-T/TCE while underscoring the importance of dynamic surveillance during therapy. Significance: Multiple myeloma has been demonstrated to recurrently develop resistance to T-cell redirection via genomic antigen escape. By leveraging chemotherapy mutational signatures, we demonstrate that somatic antigen-escape mechanisms are uniformly acquired following treatment initiation and not selected from among preexisting clones, emphasizing the importance of dynamic longitudinal surveillance for their emergence. See related commentary by Kauer et al., p. 532
- 16 October 2020
- Published by SAGE Publications in Thyroid®
- Vol. 30 (10) , 1482-1489
Sensitive Sequencing Analysis Suggests Thyrotropin Receptor and Guanine Nucleotide-Binding Protein G Subunit Alpha as Sole Driver Mutations in Hot Thyroid Nodules
Background: Constitutively activating mutations in the thyrotropin receptor ( TSHR ) and the guanine nucleotide-binding protein G subunit alpha ( GNAS ) are the primary cause of hot thyroid nodules (HTNs). The reported prevalence of TSHR and GNAS mutations in HTNs varies. Previous studies show TSHR mutations in 8–82% of HTNs and GNAS mutations in 8–75% of HTNs. With sensitive and comprehensive targeted next-generation sequencing (tNGS), we re-evaluated the prevalence of TSHR and GNAS mutations in HTNs. Methods: Samples from three previous studies found to be TSHR and GNAS mutation negative were selected and re-evaluated using high-resolution melting (HRM) PCR. Remaining mutation negative samples were further reanalyzed by tNGS with a sequencing depth between 3000 × and 10,000 × . Our tNGS panel covered the entire TSHR coding sequence along with mutation hot spots in GNAS . Sequencing reads were aligned to reference and variants were called using Torrent Suite software v5.8. Results: In total, 154 of 182 previously mutation negative HTNs were positive for TSHR or GNAS mutations, resulting in an 85% prevalence of TSHR and GNAS mutations in HTNs, 79% and 6%, respectively. In a subset of 25 HTNs with multiple samples per nodule, and analyzed by tNGS at high sequencing depth, TSHR mutations were detected in 23 (92%) HTNs and 1 GNAS mutation was detected in 1 (4%) HTN, 96% mutation positive HTNs in this subset. Conclusions: Owing to the higher sensitivity of tNGS as compared with denaturing gradient gel electrophoresis and HRM-PCR, TSHR or GNAS mutations could be detected in 85% of HTNs. The detection of TSHR and GNAS mutations occurred in 96% of HTNs in a sample set with multiple samples per nodule analyzed by tNGS. Taken together with the fact that no other driver mutations could be identified by whole exome sequencing, our study strongly supports the hypothesis that TSHR and GNAS mutations are the main somatic mutations leading to HTNs.
- 16 October 2020
- Published by SAGE Publications in Thyroid®
- Vol. 30 (10) , 1482-1489
Sensitive Sequencing Analysis Suggests Thyrotropin Receptor and Guanine Nucleotide-Binding Protein G Subunit Alpha as Sole Driver Mutations in Hot Thyroid Nodules
Background: Constitutively activating mutations in the thyrotropin receptor ( TSHR ) and the guanine nucleotide-binding protein G subunit alpha ( GNAS ) are the primary cause of hot thyroid nodules (HTNs). The reported prevalence of TSHR and GNAS mutations in HTNs varies. Previous studies show TSHR mutations in 8–82% of HTNs and GNAS mutations in 8–75% of HTNs. With sensitive and comprehensive targeted next-generation sequencing (tNGS), we re-evaluated the prevalence of TSHR and GNAS mutations in HTNs. Methods: Samples from three previous studies found to be TSHR and GNAS mutation negative were selected and re-evaluated using high-resolution melting (HRM) PCR. Remaining mutation negative samples were further reanalyzed by tNGS with a sequencing depth between 3000 × and 10,000 × . Our tNGS panel covered the entire TSHR coding sequence along with mutation hot spots in GNAS . Sequencing reads were aligned to reference and variants were called using Torrent Suite software v5.8. Results: In total, 154 of 182 previously mutation negative HTNs were positive for TSHR or GNAS mutations, resulting in an 85% prevalence of TSHR and GNAS mutations in HTNs, 79% and 6%, respectively. In a subset of 25 HTNs with multiple samples per nodule, and analyzed by tNGS at high sequencing depth, TSHR mutations were detected in 23 (92%) HTNs and 1 GNAS mutation was detected in 1 (4%) HTN, 96% mutation positive HTNs in this subset. Conclusions: Owing to the higher sensitivity of tNGS as compared with denaturing gradient gel electrophoresis and HRM-PCR, TSHR or GNAS mutations could be detected in 85% of HTNs. The detection of TSHR and GNAS mutations occurred in 96% of HTNs in a sample set with multiple samples per nodule analyzed by tNGS. Taken together with the fact that no other driver mutations could be identified by whole exome sequencing, our study strongly supports the hypothesis that TSHR and GNAS mutations are the main somatic mutations leading to HTNs.
- Open Access
- 13 July 2019
- Published by Springer Nature in Diagnostic Pathology
- Vol. 14 (1) , 1-11
MYB-NFIB gene fusions identified in archival adenoid cystic carcinoma tissue employing NanoString analysis: an exploratory study
Adenoid cystic carcinoma (ACC) is a slow growing salivary gland malignancy that is molecularly characterized by t(6:9)(q22–23;p23–24) translocations which predominantly result in MYB-NFIB gene fusions in nearly half of tumours. Detection of MYB-NFIB transcripts is typically performed with fresh ACC tissue using conventional RT-PCR fragment analysis or FISH techniques, which are prone to failure when only archival formalin fixed paraffin embedded (FFPE) tissue is available. The purpose of this pilot study was to evaluate the utility of NanoString probe technology for the detection of MYB-NFIB transcripts in archival ACC tissue. A NanoString probeset panel was designed targeting the junctions of three currently annotated MYB-NFIB fusion genes as well as 5′/3′ MYB probesets designed to detect MYB gene expression imbalance. RNA isolated from twenty-five archival ACC specimens was profiled and analyzed. RT-qPCR and sequencing were performed to confirm NanoString results. MYB protein expression was analyzed by immunohistochemistry. Of the 25 samples analyzed, 11/25 (44%) expressed a high degree of MYB 5′/3′ imbalance and five of these samples were positive for at least one specific MYB-NFIB variant in our panel. MYB-NFIB variant detection on NanoString analysis was confirmed by direct cDNA sequencing. No clinical correlations were found to be associated with MYB fusion status. We conclude that the application of NanoString digital probe counting technology is well suited for the detection and quantification of MYB-NFIB fusion transcripts in archival ACC specimens.
- 13 July 2019
- Published by Springer Nature in Diagnostic Pathology
- Vol. 14 (1) , 1-11
Open AccessMYB-NFIB gene fusions identified in archival adenoid cystic carcinoma tissue employing NanoString analysis: an exploratory study
Adenoid cystic carcinoma (ACC) is a slow growing salivary gland malignancy that is molecularly characterized by t(6:9)(q22–23;p23–24) translocations which predominantly result in MYB-NFIB gene fusions in nearly half of tumours. Detection of MYB-NFIB transcripts is typically performed with fresh ACC tissue using conventional RT-PCR fragment analysis or FISH techniques, which are prone to failure when only archival formalin fixed paraffin embedded (FFPE) tissue is available. The purpose of this pilot study was to evaluate the utility of NanoString probe technology for the detection of MYB-NFIB transcripts in archival ACC tissue. A NanoString probeset panel was designed targeting the junctions of three currently annotated MYB-NFIB fusion genes as well as 5′/3′ MYB probesets designed to detect MYB gene expression imbalance. RNA isolated from twenty-five archival ACC specimens was profiled and analyzed. RT-qPCR and sequencing were performed to confirm NanoString results. MYB protein expression was analyzed by immunohistochemistry. Of the 25 samples analyzed, 11/25 (44%) expressed a high degree of MYB 5′/3′ imbalance and five of these samples were positive for at least one specific MYB-NFIB variant in our panel. MYB-NFIB variant detection on NanoString analysis was confirmed by direct cDNA sequencing. No clinical correlations were found to be associated with MYB fusion status. We conclude that the application of NanoString digital probe counting technology is well suited for the detection and quantification of MYB-NFIB fusion transcripts in archival ACC specimens.
- 1 January 2014
- Published by Elsevier in Gynecologic Oncology
- Vol. 132 (1) , 188-193
PIK3CA missense mutation is associated with unfavorable outcome in grade 3 endometrioid carcinoma but not in serous endometrial carcinoma
- 1 January 2014
- Published by Elsevier in Gynecologic Oncology
- Vol. 132 (1) , 188-193
PIK3CA missense mutation is associated with unfavorable outcome in grade 3 endometrioid carcinoma but not in serous endometrial carcinoma